DC:LUN H. Lundbeck A/S

H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Denmark and internationally. Its products include Abilify Maintena, Brintellix/Trintellix, Cipralex/Lexapro, Northera, Onfi, Rexulti, Sabril, and Xenazine. The company offers pharmaceutical products for the treatment of Alzheimer's disease, depression, Parkinson's disease, Schizophrenia, alcohol dependence, anxiety, Bipolar I disorder, Epilepsy, Huntington's disease, and symptomatic neurogenic orthostatic hypotension. H. Lundbeck A/S sells its products to distributors of pharmaceuticals, pharmacies, and hospitals. The company was founded in 1915 and is headquartered in Valby, Denmark.This company has ADRs that trade in the U.S. as the symbol HLUYY.

172.70 EUR
As of 06/09/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Denmark
Country of incorporation:  Denmark
IPO date:  10/16/2000
Stock exchange:    Omx Nordic Exchange Copen
Exchange country:   Denmark
Market cap:   33,908,871,168 EUR
Current dividend yield:   1.20%
Sedol:      7085259

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy